Side-by-side · Research reference
GHRP-2vsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed15/42 cited
BHuman-MechanisticDraft12/36 cited
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
GHRP-2
Pinealon
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
Yes, with somatostatin feedback active
—
Origin
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-2
Pinealon
Frequency
1–3× per day
Once daily during cycle
Lower / starter dose
50 mcg per dose
2.5 mg / day
Evidence basis
Phase 2 + clinical diagnostic useBowers 1990
Russian clinical trials + in vitroKhavinson 2014
Duration
8–12 weeks on / 4 off (anecdotal)
10-day cycles, 1–2× per year
Reconstitution
Bacteriostatic water
Bacteriostatic water
Timing
Pre-sleep + fasted preferred
No specific time
04Side Effects & Safety
Parameter
GHRP-2
Pinealon
Prolactin elevation
Mild but measurable
—
Hunger
Strong appetite increase
—
Injection site reaction
Mild erythema
Mild irritation
IGF-1 elevation
Strong; monitor with chronic high-dose use
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
Avoid
Long-term safety
—
Limited Western data
Absolute Contraindications
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
GHRP-2
- ·Untreated diabetes
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
GHRP-2
Pinealon
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Injection site
SQ — abdomen or thigh. Rotate sites.
SQ — abdomen preferred.
3. Timing
Pre-sleep + fasted preferred.
Daily during cycle, any time.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation